Potential role of notch signalling in CD34+ chronic myeloid leukaemia cells: Cross-talk between notch and BCR-ABL

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Aljedai, Abdullah ^a,c   Buckle, Anne Marie ^a   Hiwarkar, Prashant ^b,d   Syed, Farhatullah ^a,c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Department of Paediatric Haematology Great Ormond Street Hospital ^*  (United Kingdom)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; HISTONE DEACETYLASE; IMATINIB; MESSENGER RNA; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR HES 1; VALPROIC ACID; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HES1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NOTCH1 PROTEIN, HUMAN; NOTCH2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA CELL; LYMPHOID PROGENITOR CELL; MYELOID PROGENITOR CELL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIGENS, CD34; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FUSION PROTEINS, BCR-ABL; HOMEODOMAIN PROTEINS; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR HES-1; TUMOR CELLS, CULTURED;

EID: 84927539484     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123016     Document Type: Article

References (63)

1. Bray SJ (2006) Notch signalling: a simple pathway becomes complex. Nature reviews Molecular cell biology 7: 678-689. PMID: 16921404
2. Guruharsha K, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nature Reviews Genetics.
3. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L (2008) Rational targeting of Notch signaling in cancer. Oncogene 27: 5124-5131. doi: 10.1038/onc.2008.226 PMID: 18758481
4. Chomel J, Aggoune D, Sorel N, Turhan A (2014) [Chronic myeloid leukemia stem cells: cross-talk with the niche]. Medecine sciences: M/S 30: 452-461. doi: 10.1051/medsci/20143004022 PMID: 24801043
5. Chen Y, Li S (2013) Molecular signatures of chronic myeloid leukemia stem cells. Biomark Res 1: 21. doi: 10.1186/2050-7771-1-21 PMID: 24252550
6. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325. PMID: 11756187
7. Kinstrie R, Copland M (2013) Targeting chronic myeloid leukemia stem cells. Current hematologic malignancy reports 8: 14-21. doi: 10.1007/s11899-012-0148-8 PMID: 23264204
8. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I (2014) Notch signaling: switching an oncogene to a tumor suppressor. Blood 123: 2451-2459. doi: 10.1182/blood-2013-08-355818 PMID: 24608975
9. Hernandez Tejada FN, Galvez Silva JR, Zweidler-Mckay PA (2014) The Challenge of Targeting Notch in Hematologic Malignancies. Pediatric Oncology 2: 54.
10. Giniger E (1998) A role for Abl in Notch signaling. Neuron 20: 667-681. PMID: 9581760
11. Crowner D, Le Gall M, Gates MA, Giniger E (2003) Notch Steers Drosophila ISNb Motor Axons by Regulating the Abl Signaling Pathway. Current biology 13: 967-972. PMID: 12781136
12. Sengupta A, Banerjee D, Chandra S, Banerji S, Ghosh R, Roy R, et al. (2007) Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21: 949-955. PMID: 17361218
13. Ishiko E, Matsumura I, Ezoe S, Gale K, Ishiko J, Satoh Y, et al. (2005) Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1. Journal of Biological Chemistry 280: 4929-4939. PMID: 15563463
14. Yin D-D, Fan F-Y, Hu X-B, Hou L-H, Zhang X-P, Liu L, et al. (2009) Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562. Leukemia research 33: 109-114. doi: 10.1016/j.leukres.2008.06.023 PMID: 18687467
15. Yang C, Chen J, Zhang S, Li F, Yang Z (2011) Effect of Overexpression of Intracellular Domain of Notch 2 Gene on Proliferation of K 562 Cells and Relevant Mechanism. Chinese Journal of Biologicals 24: 1278-1281.
16. Yang Z, Yang C, Zhang S, Li Y, Chen J (2013) Notch2 inhibits proliferation of chronic myeloid leukemia cells. Oncology letters 5: 1390-1394. PMID: 23599800
17. Jamieson C (2010) Split ends in CML: divergent roles of Hes1. Blood 115: 2726-2727. doi: 10.1182/blood-2009-12-252585 PMID: 20378758
18. Nakahara F, Kitaura J, Uchida T, Nishida C, Togami K, Inoue D, et al. (2014) Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. Blood 123: 3932-3942. doi: 10.1182/blood-2013-01-476747 PMID: 24825862
19. Burthem J, Rees-Unwin K, Mottram R, Adams J, Lucas G, Spooncer E, et al. (2007) The ρ-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34+ CML progenitor cells. Leukemia 21: 1708-1714. PMID: 17554385
20. Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+ 38- cells, through activation of protein kinase Cβ. Blood 114: 4186-4196. doi: 10.1182/blood-2009-05-219550 PMID: 19738029
21. Pellicano F, Šimara P, Sinclair A, Helgason GV, Copland M, Grant S, et al. (2011) The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 25: 1159-1167. doi: 10.1038/leu.2011.67 PMID: 21483442
22. Chadwick N, Nostro MC, Baron M, Mottram R, Brady G, Buckle AM (2007) Notch signaling induces apoptosis in primary human CD34+ hematopoietic progenitor cells. Stem Cells 25: 203-210. PMID: 16973835
23. Chadwick N, Zeef L, Portillo V, Boros J, Hoyle S, van Doesburg JC, et al. (2010) Notch protection against apoptosis in T-ALL cells mediated by GIMAP5. Blood Cells, Molecules, and Diseases 45: 201-209. doi: 10.1016/j.bcmd.2010.07.006 PMID: 20817506
24. Portillo V, Chadwick N, Lloyd R, Jackson D, Buckle AM (2013) Cell-surface Notch1 expression identifies a primitive phenotype within CD34+ CD38- haematopoietic cells. European journal of haematology.
25. Chadwick N, Zeef L, Portillo V, Fennessy C, Warrander F, Hoyle S, et al. (2009) Identification of novel Notch target genes in T cell leukaemia.Mol Cancer 8: 35. doi: 10.1186/1476-4598-8-35 PMID: 19508709
26. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ (1994) Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. Journal of Biological Chemistry 269: 22925-22928. PMID: 8083188
27. Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B, et al. (2005) Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 19: 458. PMID: 15618956
28. Diaz-Blanco E, Bruns I, Neumann F, Fischer J, Graef T, Rosskopf M, et al. (2007) Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21: 494-504. PMID: 17252012
29. Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, et al. (2009) Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23: 983-985. doi: 10.1038/leu.2008.337 PMID: 19052557
30. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127. PMID: 16632515
31. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics 34: 267-273. PMID: 12808457
32. Mizuno T, Yamasaki N, Miyazaki K, Tazaki T, Koller R, Oda H, et al. (2008) Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice. Oncogene 27: 3465-3474. doi: 10.1038/sj.onc.1211007 PMID: 18193087
33. Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167-3174. PMID: 15070699
34. Kogoshi H, Sato T, Koyama T, Nara N, Tohda S (2007) γ-Secretase inhibitors suppress the growth of leukemia and lymphoma cells. Oncology reports 18: 77-80. PMID: 17549349
35. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, et al. (2008) In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 93: 533-542. doi: 10.3324/haematol.11894 PMID: 18322257
36. Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison C, Mugneret F, et al. (2008) Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 23: 125-133. doi: 10.1038/leu.2008.278 PMID: 18923437
37. Liu N, Zhang J, Ji C (2013) The emerging roles of Notch signaling in leukemia and stem cells. Biomarker Research 1: 23. doi: 10.1186/2050-7771-1-23 PMID: 24252593
38. Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT (2002) Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99: 2369-2378. PMID: 11895769
39. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88: 2162-2171. PMID: 8822936
40. Sang L, Roberts JM, Coller HA (2010) Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends in molecular medicine 16: 17-26. doi: 10.1016/j.molmed.2009.11.001 PMID: 20022559
41. Abderrahmani A, Niederhauser G, Lenain V, Regazzi R, Waeber G (2005) The hairy and enhancer of split 1 is a negative regulator of the repressor element silencer transcription factor. FEBS letters 579: 6199-6204. PMID: 16253247
42. Eisele YS, Baumann M, Klebl B, Nordhammer C, Jucker M, Kilger E (2007) Gleevec Increases Levels of the Amyloid Precursor Protein Intracellular Domain and of the Amyloid-β-degrading Enzyme Neprilysin. Molecular biology of the cell 18: 3591-3600. PMID: 17626163
43. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107: 4532-4539. PMID: 16469872
44. He F, Wang L, Hu X-B, Yin D-D, Zhang P, Li G-H, et al. (2009) Notch and BCR signaling synergistically promote the proliferation of Raji B-lymphoma cells. Leukemia research 33: 798-802. doi: 10.1016/j.leukres.2008.09.016 PMID: 18937977
45. Han H, Tanigaki K, Yamamoto N, Kuroda K, Yoshimoto M, Nakahata T, et al. (2002) Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. International immunology 14: 637-645. PMID: 12039915
46. Grabher C, Harald von Boehmer A (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Reviews Cancer 6: 347-359. PMID: 16612405
47. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271. PMID: 15472075
48. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, et al. (2010) Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 115: 2872-2881. doi: 10.1182/blood-2009-05-222836 PMID: 19861684
49. Suresh S, McCallum L, Crawford LJ, Lu WH, Sharpe DJ, Irvine AE (2013) The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia. The Journal of pathology 231: 378-387. PMID: 24308033
50. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et al. (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature medicine 13: 1203-1210. PMID: 17873882
51. Palomero T, Dominguez M, Ferrando AA (2008) The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. CELL CYCLE-LANDES BIOSCIENCE-7: 965.
52. Burchert A, Wang Y, Cai D, Von Bubnoff N, Paschka P, Müller-Brüsselbach S, et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782. PMID: 16136169
53. Sinclair A, Latif A, Holyoake T (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. British journal of pharmacology 169: 1693-1707. doi: 10.1111/bph.12183 PMID: 23517124
54. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, et al. (2005) Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nature immunology 6: 314-322. PMID: 15665828
55. Coluccia AML, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, et al. (2007) Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. The EMBO journal 26: 1456-1466. PMID: 17318191
56. Tickenbrock L, Hehn S, Sargin B, Choudhary C, Bäumer N, Buerger H, et al. (2008) Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4. International journal of oncology 33: 1215-1221. PMID: 19020754
57. Panin VM, Irvine KD. Modulators of Notch signaling; 1998. Elsevier. pp. 609-617.
58. Foltz DR, Santiago MC, Berechid BE, Nye JS (2002) Glycogen synthase kinase-3β modulates notch signaling and stability. Current Biology 12: 1006-1011. PMID: 12123574
59. Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, et al. (2012) Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Molecular cancer therapeutics 11: 1565-1575. doi: 10.1158/1535-7163.MCT-11-0938 PMID: 22504949
60. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, et al. (2012) Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatric blood & cancer 58: 815-818.
61. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. (2012) Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of Clinical Oncology 30: 2348-2353. doi: 10.1200/JCO.2011.36.8282 PMID: 22529266
62. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 331: 598-608. doi: 10.1124/jpet.109.152975 PMID: 19671883
63. Aste-Amezaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, et al. (2010) Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 5: e9094. doi: 10.1371/journal.pone.0009094 PMID: 20161710